Afrigen
Afrigen is a South African biotechnology company specializing in vaccine development, mRNA technology transfer, and biologics. It collaborates with global health organizations like WHO and MPP to establish vaccine manufacturing capacity in Africa, aiming to improve access to life-saving vaccines and biologics in low- and middle-income countries. Afrigen operates the only adjuvant formulation laboratory in Africa and has a pipeline of vaccines in development, including efforts to produce Africa's first COVID-19 mRNA vaccines.
Industries
Nr. of Employees
small (1-50)
Afrigen
Cape Town, NA - South Africa, South Africa, Africa
Products
mRNA technology transfer hub (project)
A coordinated regional project to establish an mRNA vaccine technology-transfer hub providing training, process establishment and licences to enable local manufacturing capacity in LMICs.
Demonstration lab-scale mRNA vaccine batches
Lab- and pilot-scale production runs of an mRNA vaccine candidate produced as demonstration batches to validate processes and support technology transfer and training activities.
mRNA technology transfer hub (project)
A coordinated regional project to establish an mRNA vaccine technology-transfer hub providing training, process establishment and licences to enable local manufacturing capacity in LMICs.
Demonstration lab-scale mRNA vaccine batches
Lab- and pilot-scale production runs of an mRNA vaccine candidate produced as demonstration batches to validate processes and support technology transfer and training activities.
Services
Provision of a technology-transfer hub model that includes hands-on training, process transfer, demonstration manufacturing and technical support to establish local mRNA vaccine production capability.
Formulation and compounding of complex pure and botanical mixtures into stable delivery formats for clinical and therapeutic use.
Design and development of encapsulation systems (e.g., liposomes, emulsions) to improve shelf life, control release and enhance bioavailability of actives.
Research and formulation of adjuvant systems for use in human and veterinary vaccines.
Storage and stability‑testing services configured for different ICH climatic zones to support product stability assessment.
Provision of a technology-transfer hub model that includes hands-on training, process transfer, demonstration manufacturing and technical support to establish local mRNA vaccine production capability.
Formulation and compounding of complex pure and botanical mixtures into stable delivery formats for clinical and therapeutic use.
Design and development of encapsulation systems (e.g., liposomes, emulsions) to improve shelf life, control release and enhance bioavailability of actives.
Research and formulation of adjuvant systems for use in human and veterinary vaccines.
Storage and stability‑testing services configured for different ICH climatic zones to support product stability assessment.
Expertise Areas
- mRNA vaccine development
- Technology transfer and training for biomanufacturing
- Pilot-scale biomanufacturing and fill–finish
- Vaccine formulation and adjuvant development
Key Technologies
- mRNA production and formulation
- Liposome and emulsion encapsulation
- Adjuvant formulation
- Pilot-scale upstream and downstream bioprocessing
News & Updates
South Africa will host the first WHO mRNA technology transfer hub, aiming to produce vaccines locally and improve regional health security.
Afrigen is preparing to produce Africa's first COVID-19 mRNA vaccines within 15 months of signing a technology transfer agreement.
Afrigen's MD discusses the company's efforts to produce mRNA vaccines similar to Moderna's in collaboration with WHO.
Celebrating women contributing to science and innovation.
South Africa will host the first WHO mRNA technology transfer hub, aiming to produce vaccines locally and improve regional health security.
Afrigen is preparing to produce Africa's first COVID-19 mRNA vaccines within 15 months of signing a technology transfer agreement.
Afrigen's MD discusses the company's efforts to produce mRNA vaccines similar to Moderna's in collaboration with WHO.
Celebrating women contributing to science and innovation.